Today, Novo commands a market capitalization of roughly $230.4 billion, underscoring its scale and influence in the global pharma landscape. Even so, the stock hasn’t had a smooth ride in 2025. Multiple factors, including soft demand for its blockbuster drugs and intensifying competition in the weight-loss space, have eroded investor confidence.Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is one of the world’s most influential healthcare companies, with a deep-rooted foc ...